All News

Some of the analyzed dietary supplement products were found to contain FDA-prohibited substances.

The study authors said that further investigation is needed to explore specialized care for mothers and newborns who are affected by hepatitis C infections during pregnancy.

John Beckner from the National Community Pharmacists Association speaks with Ben McNabb and Mayank Parikh about pharmacies becoming a major health care destination for patients.

Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Exercise alone or vitamin D supplementation did not clinically improve cognition in adults with mild cognitive impairment.

The once-daily therapeutic agent is effective for pediatric patients and pregnant women with HIV.

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.

Legislation would place emphasis back on patient health rather than on cumbersome, time-consuming paperwork.

Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.

Notably, the risk of cognitive impairment among retired professional soccer players grows larger by position, with those such as forwards and defenders being most at risk.

A company’s choice of color for branding and logo design may impact how consumers feel about the brand and could influence buyer decision-making.

Building on promising prior research, ERβ was found to prevent aggressive forms of breast cancer from metastasizing.

The findings showed that interventions to improve sleep could be key to maintaining cognitive function, with investigators calling for further studies.

The research narrows the most at-risk populations and how to mitigate the impacts on adults with ADRD.

Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.

Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.

There are currently no effective treatments for CIPN prevention.

Individuals with age-related hearing loss should not be treated with “standard” hearing aids, but fitted to their personal needs, while avoiding settings that add distortion.

The approval carries the limitation that bexagliflozin may increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.

For adolescents and young adults affected by HIV, Google yielded higher quality information on pre-exposure prophylaxis more frequently compared to other search engines.

Quitting treatment may significantly improve severe hypertension in patients with hepatocellular carcinoma.

Not only is a combination of in-office visits and telemedicine an effective model of prenatal care, but it can be an alternative to those who face access barriers.

A smartwatch may be able to replace a sleep diary to evaluate falling asleep and waking times for those with insomnia.

Many living in lower-income rural populations face significant unmet social needs that can bar access to important mental health services.

Managing cost savings can soften the blow of direct and indirect remuneration fee reform that will impact pharmacists during the first half of 2024.